December 28, 2001CancerOpen Access

Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma

View Full Paper

Ask AI

Bookmark

Why the study?

Does liposome-encapsulated doxorubicin reduce cardiotoxicity compared to conventional doxorubicin in patients with metastatic breast carcinoma?

Structured PICO

Does liposome-encapsulated doxorubicin reduce cardiotoxicity compared to conventional doxorubicin in patients with metastatic breast carcinoma?

Population

224 patients with metastatic breast carcinoma (MBC) and no prior therapy for metastatic disease, median age 54 years.

Intervention

Liposome-encapsulated doxorubicin (TLC D-99) 75 mg/m2 every 3 weeks in the absence of disease progression or unacceptable toxicity.

Comparator

Conventional doxorubicin 75 mg/m2 every 3 weeks in the absence of disease progression or unacceptable toxicity.

Outcome

Response rate (primary efficacy endpoint) and cardiotoxicity (primary safety endpoint, defined by LVEF decline or clinical CHF).safety

Liposome-encapsulated doxorubicin significantly reduces cardiotoxicity compared to conventional doxorubicin while maintaining comparable antitumor efficacy in patients with metastatic breast cancer.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Supports liposomal doxorubicin to reduce cardiotoxicity risk in metastatic breast cancer; confirms RCT benefit of encapsulation versus conventional formulation.

Cite This Study

Harris et al. (2001) studied this question.

synapsesocial.com/papers/6a7d280cdd3961f7384256ca https://doi.org/10.1002/cncr.10201

Topics

Heart failure HFrEF treatment

View Full Paper

Ask AI

Bookmark

Implication

Supports liposomal doxorubicin to reduce cardiotoxicity risk in metastatic breast cancer; confirms RCT benefit of encapsulation versus conventional formulation.

Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma

Structured PICO

Discussion

Implication

Cite This Study

Topics

Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider